Global Coagulation Testing Market Size is Expected to Reach USD 2.69 Billion by 2021: Technavio

Technavio has published a new report on the global coagulation testing market from 2017-2021. (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

LONDON--()--According to the latest market study released by Technavio, the global coagulation testing market is expected to grow at a CAGR of more than 6% during the forecast period.

This research report titled ‘Global Coagulation Testing Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The global coagulation testing market size is expected to grow to USD 2.69 billion by 2021, with the Americas responsible for generating the maximum revenue and the highest incremental growth in the forecast period.

The major driver behind the dominance of the Americas is the improved clinical diagnostic procedures and favorable initiatives conducted by the World Health Organization (WHO) towards the development of novel products. Technological advancements in product design, structure, usage, and the availability of reimbursements are driving the growth of the market in the region.

Request a sample report: http://www.technavio.com/request-a-sample?report=56321

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Based on application, the report categorizes the global coagulation testing market into the following segments:

  • Prothrombin time (PT)
  • Activated partial thromboplastin time (aPTT)
  • Thrombin time (TT)
  • Activated clotting time (ACT)

The top three revenue-generating application segments in the global coagulation testing market are discussed below:

Prothrombin time (PT)

Prothrombin time tests are used to measure the time taken for the liquid part of the blood to form a clot. This test helps in determining warfarin dosage, liver damage, vitamin K status, and to detect liver disorders,” says Srinivas Sashidhar, one of the lead analysts at Technavio for in-vitro diagnostics research.

INR blood tests or PT-INR testing comprises over 71% of the coagulation testing market, driven by high preference towards the anti-coagulation agent warfarin by physicians. The growing patient population, ongoing use of warfarin, increased testing frequency, and strong reimbursements for medical practitioners are responsible for the dominance of this market segment.

Activated partial thromboplastin time (aPTT)

Activated partial thromboplastin time (aPTT) is used to analyze blood clotting by measuring the intrinsic pathway. An intrinsic pathway consists of several proteins, known as coagulation factors, which can be used to monitor the patient’s response to heparin therapy, ensuring the consistency of blood. Point-of-care-testing devices usually perform this test, and Alere is the leading player in the market segment.

Thrombin time (TT)

Thrombin time is a type of blood test, which helps in measuring the amount of time blood takes to form a clot in the presence of an anticoagulant. The effectiveness of fibrinolytic therapy and blood coagulation disorders can be established with the help of these tests,” says Srinivas.

Thrombin time tests are used to assess abnormal blood clotting, such as disseminated intravascular coagulation (DIC), and other conditions. Abbott Laboratories and Siemens Healthcare are the major players in this market segment.

The top vendors highlighted by Technavio’s research analysts in this report are:

  • Roche Diagnostics
  • Alere
  • Abbott Laboratories
  • Siemens Healthcare

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, medical imaging, and patient monitoring devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

According to the latest market study released by Technavio, the global coagulation testing market is expected to grow at a CAGR of more than 6% during the forecast period.

$Cashtags

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com